Related Experiment Video
Updated: Aug 5, 2026

Protective Efficacy and Pulmonary Immune Response Following Subcutaneous and Intranasal BCG Administration in Mice
Published on: September 19, 2016
Nirsevimab and Hospitalization for Lower Respiratory Tract Infection During the Second Season
David Moreno-Pérez1,2,3,4, Esther Catalán-Fernández5, Borja Croche-Santander6
1Department of Health, Presidency and Emergencies, General Directorate of Public Health and Pharmaceutical Management of Andalusia, Seville, Spain.
Objectives:
To assess the effect of nirsevimab in preventing hospitalizations for lower respiratory tract infection (LRTI) during the second respiratory season of life among infants who were administered nirsevimab in their first months of life.
Methods:
Community-based case-control study conducted in 9 tertiary pediatric hospitals in Andalusia, Southern Spain. Infants born between April 1, 2023, and March 31, 2024, were included. Cases were infants hospitalized for LRTI during the 2024 to 2025 season. For each case, 4 community controls were matched by birthdate and province. Exposure was nirsevimab administration during the 2023 to 2024 respiratory syncytial virus (RSV) season. The main outcome was hospitalization for LRTI during the 2024 to 2025 season. Inverse probability weighting (IPW) and doubly robust augmented IPW (AIPW) models were used to estimate the average treatment effect, expressed as absolute risk reduction (ARR).
Results:
The study included 1375 infants (275 cases and 1100 controls). Nirsevimab administration during the 2023 to 2024 season was associated with a 17.0% ARR (95% CI, 3.2%-30.8%) in LRTI hospitalizations during the 2024 to 2025 season in the AIPW model. Stronger associations were observed among RSV-positive cases (ARR = 25.4%; 95% CI, 4.9%-45.8%) and in infants with a history of inhaler use (ARR = 27.7%; 95% CI, 6.4%-48.9%). A negative control exposure (rotavirus vaccination) showed no association, supporting no evidence of relevant residual confounding regarding health-seeking behaviors.
Conclusions:
Nirsevimab administration was associated with a reduction in second-season LRTI hospitalizations, suggesting meaningful benefits beyond the season of administration and potential implications for future cost-effectiveness evaluations.
Related Concept Videos
Respiratory Syncytial Virus Disease
Influenza
Upper Respiratory Drugs: First and Second-Generation Antihistamines
Histamine binds to specific receptor sites, known as H1 receptors, on tissue cells, triggering inflammation and swelling. Antihistamines combat these effects by competing with histamine for these receptor sites. By...
Vaccinations
Pneumonia V: Nursing management and Prevention
The nurse must practice strict medical asepsis and adhere to infection control guidelines to minimize healthcare-associated infections.
Enhance airway patency
Position the patient correctly to facilitate drainage of the affected lung segments. Manual or mechanical percussion and vibration can also be employed.
Pneumonia IV: Management
Bacterial Pneumonia Treatment
For bacterial pneumonia, antibiotics serve as the cornerstone of therapy. Initial treatment often begins with empirical antibiotics, tailored to the anticipated causative organism and adjusted based on culture results. Key antibiotic choices include:
